Sutro Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. on November 8, 2018. The report discloses corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and related compensation.
Material Changes
On November 8, 2018, the Board of Directors appointed Shalini Sharp as a Class III director and Chair of the Audit Committee. The following compensatory arrangements were established:
- Annual Retainer: Pro rata portion of $35,000 for director service and $15,000 for Audit Committee Chair service for the remainder of the year.
- Stock Option Grant: Option to purchase 26,033 shares of common stock at an exercise price of $14.23 per share.
- Vesting Schedule: Monthly vesting over three years, contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No risks or contingencies were disclosed in this specific report. The Company confirmed there are no undisclosed arrangements regarding Ms. Sharp's selection and no family relationships with other directors or officers.
Key Facts for Investor Verification
- Confirmation of Shalini Sharp's appointment as Class III Director and Audit Committee Chair.
- Total equity grant size of 26,033 shares and the $14.23 exercise price.
- Verification of the three-year monthly vesting schedule.
- Confirmation that no other material transactions or relationships exist involving the new director.